Are more complex implantable cardioverter defibrillators associated with an increased mortality? Lessons learned from clinical trials

K A Ellenbogen; A E Epstein; M A Wood; B S Stambler; G N Kay; V J Plumb; L Voshage-Stahl; M L Hull

doi:10.1016/s0002-9149(97)00555-9

Are more complex implantable cardioverter defibrillators associated with an increased mortality? Lessons learned from clinical trials

Am J Cardiol. 1997 Oct 1;80(7):958-60. doi: 10.1016/s0002-9149(97)00555-9.

Authors

K A Ellenbogen¹, A E Epstein, M A Wood, B S Stambler, G N Kay, V J Plumb, L Voshage-Stahl, M L Hull

Affiliation

¹ Department of Medicine, Medical College of Virginia and the McGuire VA Medical Center, Richmond 23298-0053, USA.

PMID: 9382018
DOI: 10.1016/s0002-9149(97)00555-9

Abstract

We compared 1-year survival in patients receiving implantable cardioverter defibrillators (ICDs) that provide only shock therapy with more advanced ICDs that provide antitachycardia pacing, bradycardia pacing, low-energy cardioversion, and advanced detection algorithms. Outcome in patients with advanced-generation ICD systems was similar or improved compared with outcome in patients receiving ICDs with only monophasic shock.

MeSH terms

Clinical Trials as Topic
Death, Sudden, Cardiac / etiology*
Defibrillators, Implantable / adverse effects*
Equipment Design
Equipment Failure
Female
Humans
Male
Middle Aged
Survival Analysis
Tachycardia / complications
Tachycardia / mortality*
Tachycardia / therapy